New insight into Huntington’s disease may open door to drug development
Researchers have developed a new theory on Huntington’s disease which is being welcomed for showing promise to open new avenues of drug development for the condition…
Researchers have developed a new theory on Huntington’s disease which is being welcomed for showing promise to open new avenues of drug development for the condition.
Huntington’s disease is caused by a mutation in the gene that makes the protein called huntingtin. A team of researchers led by McMaster University have found there is a unique type of signalling coming from damaged DNA, that signals huntingtin activity in DNA repair, and that this signalling is defective in Huntington’s disease.
“The concept was that if we applied the signalling molecule back in excess, even orally, this signalling can be restored in the Huntington’s disease mouse brain,” said researcher Laura Bowie, a PhD student in the Department of Biochemistry and Biomedical Sciences at McMaster. “The net result was that we fixed the modification of huntingtin not seen in mutant huntingtin in Huntington’s disease.”
Using this hypothesis, the study team discovered a molecule called N6-furfuryladenine, derived from the repair of DNA damage, which corrected the defect seen in mutant huntingtin.
“Based on dosing by different ways of this molecule in mouse Huntington’s disease models, Huntington’s disease symptoms were reversed,” said Ms Bowie. “The mutant huntingtin protein levels were also restored to normal, which was a surprise to us.”
Ray Truant, the senior author on the study, has dedicated his career to Huntington’s disease research and how mutation leads to Huntington’s disease. His lab was the first to show that normal huntingtin was involved in DNA repair.
Prof Truant argues that the traditional and controversial amyloid/protein misfolding hypothesis, where a group of proteins stick together forming brain deposits, is likely the result of the disease, rather than its cause.
He said he considers this paper the most significant of his career.
“This is an important new lead and a new hypothesis, but it is important for people to know this is not a drug or cure,” said Prof Truant, of the Department of Biochemistry and Biomedical Sciences at McMaster.
“This is the first new hypothesis for Huntington’s disease in 25 years that does not rely on the version of the amyloid hypothesis which has consistently failed in drug development for other diseases.”
Huntington’s disease is a hereditary, neurodegenerative illness with devastating physical, cognitive and emotional symptoms. Worldwide, approximately one of every 7,000 people can develop Huntington’s disease. Currently, there is no treatment available to alter the course of the disease.
The study is an original and important contribution to the field of neurodegeneration, says Yves Joanette, scientific director of the Canadian Institutes of Health Research Institute of Aging.
“This research shows how complex and diverse the routes to neurodegenerative processes in the brain can be,” said Joanette. “This study will inspire not only research on Huntington’s disease but also in some of the contributing processes to the development of many other neurodegenerative diseases.”
Bev Heim-Myers, CEO of the Huntington Society of Canada, said: “The Huntington Society of Canada is proud to support such leading-edge research.”
“Innovative research initiatives, such as the work led by the team in Prof Truant’s lab, including PhD student Laurie Bowie, has the potential to transform HD research. The answers we find for Huntington’s disease will likely lead to better understanding of treatments for other neurological diseases and it is important that we continue this cross-talk amongst neurodegenerative diseases.”
The new hypothesis has been published in the Proceedings of the National Academy of Sciences (PNAS).